Retatrutide Nausea and Vomiting: How Long It Lasts and How to Stop It

Retatrutide nausea hit about 4 in 10 people on 12 mg (42.4%) in TRIUMPH-1, against 14.8% on placebo, and it bunches up in the weeks after each dose increase. It runs lower in people with type 2 diabetes, and in the first head-to-head trial 12 mg matched Ozempic 2 mg (23.8% vs 21.3%). Starting at 2 mg is the one fix retatrutide's own trials have measured.

Does retatrutide cause nausea? What the trials show

Yes, and the higher the dose, the more often. In TRIUMPH-1, Lilly's 80-week Phase 3 trial in 2,339 adults with obesity or overweight, nausea was the most common side effect at every dose. Vomiting climbed the same way. The NEJM paper (Sep 29, 2026) agrees: the most common adverse events were gastrointestinal.

So can reta make you throw up? Yes. About 1 in 4 people on 12 mg vomited at some point (25.3%), compared with about 1 in 20 on placebo (4.8%). TRIUMPH-4, a 445-person trial in adults with excess weight and knee osteoarthritis, landed in the same place: nausea in 38.1% on 9 mg and 43.2% on 12 mg, and vomiting in 20.4% and 20.9%, against 10.7% and 0.0% on placebo.

Placebo groups had nausea too, so not every queasy day is the drug. And 4 mg, reached with a single step up from 2 mg, had fewer people stop for side effects than placebo while still averaging 19.0% weight loss at 80 weeks (Lilly's efficacy estimand). Those stopping figures cover side effects of every kind. In the Phase 2 trial, stomach side effects were dose-related and mostly mild to moderate.

How retatrutide nausea compares across trials, and with Ozempic

Six Phase 3 trials have reported. At the top dose, nausea ran from 22.4% to 43.2%, depending on who was in the trial.

Figures are from Lilly's releases, plus the TRIUMPH-2 paper in The Lancet. Nausea was highest in the two trials of people without diabetes and lower in the four that enrolled people with type 2 diabetes or heart disease. Our read: the gap shows in the numbers, but the trials differ in length, population and placebo rates, so it's not a rule that diabetes protects you from nausea.

TRANSCEND-T2D-2 is the only trial that sets retatrutide beside another drug. In adults with type 2 diabetes on metformin, nausea was 21.2% on 9 mg and 23.8% on 12 mg, against 21.3% on Ozempic 2 mg over 80 weeks. These are Lilly's efficacy-estimand figures from an open-label trial, and no paper has followed yet.

For tirzepatide there's no direct comparison yet. The FDA labels list nausea in 25% to 29% of people on tirzepatide (8% on placebo) and 44% on semaglutide 2.4 mg (16% on placebo). Those come from different trials in different people, so this isn't a head-to-head, but retatrutide sits in the same range. TRIUMPH-5, retatrutide against tirzepatide, hasn't reported; the registry estimates its primary completion for November 2026. Our retatrutide vs Mounjaro page covers the rest.

Why a 2 mg start matters so much

The Phase 2 obesity trial tested the starting dose directly. Its 338 adults got placebo or a target dose from 1 mg to 12 mg, and two targets, 4 mg and 8 mg, were each reached from either a 2 mg or a 4 mg first dose. The registry results show what that single change did.

At the same 8 mg target, starting at 2 mg cut nausea from 60.0% to 17.1% and vomiting from 25.7% to 5.7%. The NEJM abstract says the same thing: gastrointestinal (GI) events were dose-related, mostly mild to moderate, and partly reduced by a lower starting dose (2 mg vs 4 mg). Groups were small, 33 to 70 people each, so treat the exact percentages as rough. The Phase 2 type 2 diabetes trial in The Lancet showed the same pattern: nausea hit 8.7% vs 25.0% at a 4 mg target, and 26.9% vs 41.7% at 8 mg, for a 2 mg vs 4 mg start.

Phase 3 used the 2 mg start for everyone. Everyone assigned to retatrutide in the TRIUMPH trials started at 2 mg and moved up one step every 4 weeks, through 4, 6 and 9 mg to 12 mg. Our starting dose guide goes through the Phase 2 comparison, and the retatrutide dosing schedule maps every step week by week.

Why does reta make you nauseous?

Blame a slower stomach and a stronger fullness signal. Retatrutide activates three hormone receptors: GIP, GLP-1 and glucagon. It shares the GLP-1 signal with tirzepatide and semaglutide, and both of their FDA labels state that the drug delays gastric emptying. Food sits in your stomach longer, so a portion that used to feel normal can leave you overfull and queasy. GLP-1 receptors also sit in brain areas that regulate appetite, which is part of how these drugs turn hunger down.

The tirzepatide label says the stomach-emptying delay is largest after the first dose and diminishes over time. Each increase brings a bigger effect your body hasn't adjusted to yet, which fits nausea bunching up after each step. Vomiting and diarrhea also drain fluids, so feeling faint or wiped out can be fluid loss. The trials don't separate what each of retatrutide's three signals adds, so class evidence is the best guide for now.

How long does retatrutide nausea last?

The trials answer in weeks, not days. In Phase 2, GI side effects were dose-related, and in TRANSCEND-T2D-1 Lilly reported nausea, diarrhea and vomiting mainly during escalation.

In Phase 3, that meant a new step every 4 weeks, and 12 mg began at week 17. Reaching it takes 16 weeks of escalation, so the stretch when nausea is likeliest to come and go can run about four months. The Zepbound label shows the same shape: most nausea, vomiting and diarrhea happened during dose escalation and decreased over time.

How fast does reta make you nauseous? Lilly Medical Information puts the time to peak blood level at 12 to 72 hours after a dose, and the half-life at about 6 days, so each weekly shot keeps working all week. If nausea follows the peak, the first one to three days after a shot would be the roughest. No trial has timed nausea against the shot, so that's an inference. The best time to take retatrutide page works through morning and night shots, and the half-life page shows how slowly a dose clears.

No trial result we found gives a day count for one bout. A BMJ Case Reports paper (Oct 7, 2026) describes a woman in her mid-20s with 5 days of refractory nausea and vomiting after 4 weekly, dose-escalated injections of an unverified product reported to contain retatrutide. It resolved within a week. That's one person and an unverified product, so it says little about trial-dose retatrutide.

Nausea that keeps going on a steady dose, weeks after your last increase, doesn't fit the usual pattern and is worth a call to your doctor. For the timelines of other side effects, see how long retatrutide side effects last.

What do people on Reddit report?

Forum posts aren't evidence, but a JAMA Network Open study (Oct 14, 2026) sorted 148,640 retatrutide posts and comments with an AI classifier. Among the 7,823 users in its analysis, nausea came up for 11.6%, behind increased appetite (17.1%) and fatigue (15.2%). Don't set that against a trial rate. These are self-reports about non-approved products of unknown content and dose, and people post about what stood out rather than everything they felt.

How to stop nausea from retatrutide

Dose pacing is the only nausea fix that retatrutide trials have measured, and it moved the numbers a lot. Food and fluids come next.

Give each dose step more time

The FDA label for semaglutide tells prescribers to consider delaying the next increase by 4 weeks when a dose isn't tolerated. The tirzepatide label says to consider a lower maintenance dose if the current one isn't tolerated. The retatrutide data point the same way: a slower start meant less nausea, and 4 mg alone averaged 19.0% weight loss in TRIUMPH-1. Make those calls with a doctor rather than on a hunch.

Breaks count too. The semaglutide label says that after 2 or more missed weekly doses, dose escalation should restart at a lower dose to reduce stomach side effects. Jumping straight back to your old dose after a break skips the ramp that protects your stomach.

Dose accuracy matters as well. Australia's TGA tested one vial sold as retatrutide and found no retatrutide in it, plus semaglutide at about 8 times the level in approved semaglutide products. The consumer behind that report had uncontrollable vomiting, a torn esophagus and hospital treatment. If you're comparing retatrutide for sale, favor sellers that publish batch-specific lab tests, so the milligrams you measure match the milligrams in the vial.

Eat for a slower stomach

Lilly's patient advice for nausea on tirzepatide fits the mechanism, and it costs nothing to try:

• Split 3 daily meals into 4 or more smaller ones.
• Stop eating as soon as you feel full.
• Avoid fatty foods like butter and cheese.
• Lean on bland foods such as toast, crackers or rice.

Alcohol stacks onto queasy weeks, which our retatrutide and alcohol guide covers.

Keep fluids coming

Vomiting and diarrhea pull water out fast. The Zepbound medication guide calls drinking fluids important to lower the chance of dehydration, which can lead to kidney problems. For diarrhea, Lilly's tirzepatide tips suggest at least 8 to 10 glasses of clear fluids a day, with water preferred. Our retatrutide diarrhea page covers that side.

What about anti-nausea medicine?

We found no published retatrutide trial that tested anti-nausea drugs alongside it. If food changes and slower steps aren't enough, ask a doctor, who can choose an option that fits your health and your other medicines.

When vomiting means you should call a doctor

Most trial nausea was mild to moderate, but not all. The UK medicines regulator, the MHRA, says nausea, vomiting and diarrhea from GLP-1 medicines sometimes lead to severe dehydration that needs hospital care. The tirzepatide label adds that most reported cases of acute kidney injury occurred in people dehydrated by these same side effects.

Two other conditions can hide behind ordinary-feeling nausea. The FDA labels warn about pancreatitis, which causes severe belly pain that won't go away and may spread to the back. The tirzepatide label also lists gallbladder problems, with upper belly pain, fever, yellow skin or eyes, or clay-colored stools.

In the Phase 2 obesity trial these were rare but real. Among 267 people on retatrutide, the registry lists one serious case each of acute pancreatitis, acute gallbladder inflammation and acute kidney injury.

For the bigger safety picture, see our guide to whether retatrutide is safe.